Literature DB >> 16912174

Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.

Yun Zhu1, Lacey L Sullivan, Sujit S Nair, Christopher C Williams, Arvind K Pandey, Luis Marrero, Ratna K Vadlamudi, Frank E Jones.   

Abstract

Although crosstalk between cell-surface and nuclear receptor signaling pathways has been implicated in the development and progression of endocrine-regulated cancers, evidence of direct coupling of these signaling pathways has remained elusive. Here we show that estrogen promotes an association between extranuclear estrogen receptor alpha (ER) and the epidermal growth factor receptor (EGFR) family member ERBB4. Ectopically expressed as well as endogenous ERBB4 interacts with and potentiates ER transactivation, indicating that the ERBB4/ER interaction is functional. Estrogen induces nuclear translocation of the proteolytic processed ERBB4 intracellular domain (4ICD) and nuclear translocation of 4ICD requires functional ligand-bound ER. The nuclear ER/4ICD complex is selectively recruited to estrogen-inducible gene promoters such as progesterone receptor (PgR) and stromal cell-derived factor 1 (SDF-1) but not to trefoil factor 1 precursor (pS2). Consistent with 4ICD-selective promoter binding, suppression of ERBB4 expression by interfering RNA shows that 4ICD coactivates ER transcription at the PgR and SDF-1 but not the pS2 promoter. Significantly, ERBB4 itself is an estrogen-inducible gene and the ERBB4 promoter harbors a consensus estrogen response element (ERE) half-site with overlapping activator protein-1 elements that bind ER and 4ICD in response to estrogen. Using a cell proliferation assay and a small interfering RNA approach, we show that ERBB4 expression is required for the growth-promoting action of estrogen in the T47D breast cancer cell line. Our results indicate that ERBB4 is a unique coregulator of ER, directly coupling extranuclear and nuclear estrogen actions in breast cancer. We propose that the contribution of an autocrine ERBB4/ER signaling pathway to tumor growth and therapeutic response should be considered when managing patients with ER-positive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912174     DOI: 10.1158/0008-5472.CAN-05-4397

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Authors:  Anjali Naresh; Ann D Thor; Susan M Edgerton; Kathleen C Torkko; Rakesh Kumar; Frank E Jones
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 2.  Biological function of nuclear receptor tyrosine kinase action.

Authors:  Sungmin Song; Kenneth M Rosen; Gabriel Corfas
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

3.  Estrogen receptor β (ERβ1) transactivation is differentially modulated by the transcriptional coregulator Tip60 in a cis-acting element-dependent manner.

Authors:  Ming-Tsung Lee; Yuet-Kin Leung; Irving Chung; Pheruza Tarapore; Shuk-Mei Ho
Journal:  J Biol Chem       Date:  2013-07-15       Impact factor: 5.157

Review 4.  Presenilin: RIP and beyond.

Authors:  Matthew R Hass; Chihiro Sato; Raphael Kopan; Guojun Zhao
Journal:  Semin Cell Dev Biol       Date:  2008-11-27       Impact factor: 7.727

5.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

6.  27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.

Authors:  Carolyn D DuSell; Michihisa Umetani; Philip W Shaul; David J Mangelsdorf; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2007-09-13

7.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.

Authors:  Christopher S Williams; Jessica K Bernard; Michelle Demory Beckler; Dana Almohazey; Mary Kay Washington; Jesse J Smith; Mark R Frey
Journal:  Carcinogenesis       Date:  2015-04-27       Impact factor: 4.944

Review 8.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

Review 9.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

10.  Nuclear transit of the intracellular domain of the interferon receptor subunit IFNaR2 requires Stat2 and Irf9.

Authors:  Ashraf El Fiky; Pete Pioli; Arif Azam; Kiwon Yoo; Kent L Nastiuk; John J Krolewski
Journal:  Cell Signal       Date:  2008-03-21       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.